کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4208588 | 1280454 | 2011 | 7 صفحه PDF | دانلود رایگان |
BackgroundPancreatic enzyme replacement therapy (PERT) is critical for correction of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).MethodsThis was a randomized, placebo-controlled PERT withdrawal study evaluating the efficacy and safety of PANCREAZE® (pancrelipase) in CF patients with EPI. Participants (n = 49) entered an open-label, ≤ 14 day run-in phase, maintained a high-fat diet (100 ± 15 g/day), and received PANCREAZE® (10.5 or 21). Participants with a coefficient of fat absorption (CFA) ≥ 80% (n = 40) were then randomized (1:1) to receive either PANCREAZE® or placebo during a double-blind, ≤ 7 day withdrawal phase.ResultsPANCREAZE® improved fat absorption as shown by significantly lower mean ± SD change in CFA between open-label and double-blind phases for PANCREAZE® (− 1.5 ± 5.88%; p < 0.001) compared to placebo (− 34.1 ± 23.03%). Protein absorption was similarly improved. No unexpected adverse events were reported.ConclusionsThis study demonstrated PANCREAZE® was effective in treating EPI due to CF and was safe and well tolerated.
Journal: Journal of Cystic Fibrosis - Volume 10, Issue 5, September 2011, Pages 350–356